Monograph

J07CA02 - Diphtheria-Pertussis-Poliomyelitis-Tetanus

Propably not porphyrinogenic

Rationale

Based on the pharmacokinetics of the diphtheria-pertussis-poliomyelitis-tetanus vaccine, there are no conceivable porphyrinogenic effects.

Chemical description

Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid and inactivated poliovirus (type 1,2 and 3) (DTP-IPV)

Therapeutic characteristics

The DTP-IPV vaccine is indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis both for primary immunization and for following booster doses. It is administered by intramuscular injections.

Metabolism and pharmacokinetics

The DTP-IPV vaccine is not metabolized by the cytochrome P450 system.

Similar drugs

Explore alternative drugs in similar therapeutic classes J07C / J07CA or go back.

References

#	Citation details	PMID
*	Government bodies
1.	Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
*	Summary of Product Characteristics
2.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tetravac. (Last edition: 30.06 2014).

Citation details

PMID

Government bodies

Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tetravac. (Last edition: 30.06 2014).

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames